Researchers are testing a type of targeted therapy called a PARP inhibitor for cancers carrying the PALB2 mutation.
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
Because Helene Avraham-Katz has the BRCA2 mutation, certain chemotherapies work better and she is eligible for specific clinical trials.
Chris Treubert started with one type of chemotherapy but when the results of genetic testing showed a BRCA mutation he changed treatment.
Harvey Parker had genetic testing as part of his initial pancreatic cancer treatment. The BRCA2 mutation led him to a PARP inhibitor clinical trial.
A study by Dr. Gloria Petersen’s research team has led to an official recommendation that all pancreatic cancer patients get genetic testing.
Researchers are combining immunotherapy and targeted therapy in a clinical trial for pancreatic cancer patients on platinum-based chemotherapy.
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
When Florida resident Doron Broman was diagnosed with stage IV pancreatic cancer, his decision to get treated in Boston gave him access a PARP inhibitor for maintenance.